fasudil has been researched along with Hypertension in 28 studies
fasudil: intracellular calcium antagonist; structure in first source
fasudil : An isoquinoline substituted by a (1,4-diazepan-1-yl)sulfonyl group at position 5. It is a Rho-kinase inhibitor and its hydrochloride hydrate form is approved for the treatment of cerebral vasospasm and cerebral ischemia.
Hypertension: Persistently high systemic arterial BLOOD PRESSURE. Based on multiple readings (BLOOD PRESSURE DETERMINATION), hypertension is currently defined as when SYSTOLIC PRESSURE is consistently greater than 140 mm Hg or when DIASTOLIC PRESSURE is consistently 90 mm Hg or more.
| Excerpt | Relevance | Reference |
|---|---|---|
| " In the present study, the effect of a subdose of fasudil, a selective ROCK inhibitor, on systemic hypertension and myocardium fibrosis induced by aldosterone was investigated in uninephrectomized Sprague-Dawley rats (SD)." | 7.77 | Subdose of fasudil suppresses myocardial fibrosis in aldosterone-salt-treated uninephrectomized rats. ( Guo, P; Masaki, T; Mori, H; Nishiyama, A; Wu, C, 2011) |
| "These results suggest that fasudil has beneficial effects on retinal vascular complications associated with chronic hypertension." | 7.74 | Vasodilator effects of fasudil, a Rho-kinase inhibitor, on retinal arterioles in stroke-prone spontaneously hypertensive rats. ( Ishii, K; Kametaka, S; Mori, A; Nakahara, T; Okamura, N; Saito, M; Sakamoto, K, 2007) |
| " A selective Rho-kinase inhibitor, fasudil, has recently been shown to improve renal damage resulting from hypertensive glomerulosclerosis, unilateral ureteral obstruction (for interstitial renal fibrosis) and subtotal nephrectomy." | 4.83 | Molecular mechanisms and therapeutic strategies of chronic renal injury: role of rho-kinase in the development of renal injury. ( Hayashi, K; Homma, K; Kanda, T; Saruta, T; Sugano, N; Wakino, S, 2006) |
| "Twenty 12-week-old healthy male Sprague-Dawley rats were randomly divided into groups A (control), B (hypertension) and C (fasudil treatment)." | 3.78 | [Fasudil improves erectile function of hypertensive rats]. ( Chen, F; Cheng, Y; Jiang, R; Ma, ZP; Yang, HF, 2012) |
| " In the present study, the effect of a subdose of fasudil, a selective ROCK inhibitor, on systemic hypertension and myocardium fibrosis induced by aldosterone was investigated in uninephrectomized Sprague-Dawley rats (SD)." | 3.77 | Subdose of fasudil suppresses myocardial fibrosis in aldosterone-salt-treated uninephrectomized rats. ( Guo, P; Masaki, T; Mori, H; Nishiyama, A; Wu, C, 2011) |
| "These results suggest that fasudil has beneficial effects on retinal vascular complications associated with chronic hypertension." | 3.74 | Vasodilator effects of fasudil, a Rho-kinase inhibitor, on retinal arterioles in stroke-prone spontaneously hypertensive rats. ( Ishii, K; Kametaka, S; Mori, A; Nakahara, T; Okamura, N; Saito, M; Sakamoto, K, 2007) |
| "To determine the effects of fasudil, a Rho-kinase inhibitor, on mineralocorticoid-induced myocardial remodeling, we investigated whether fasudil would suppress myocardial fibrosis and inflammation in deoxycorticosterone-acetate (DOCA)/salt hypertensive rats." | 3.74 | Fasudil attenuates myocardial fibrosis in association with inhibition of monocyte/macrophage infiltration in the heart of DOCA/salt hypertensive rats. ( Inoue, H; Ishimaru, K; Kagitani, S; Takabayashi, D; Takata, M; Ueno, H, 2007) |
| "We investigated the effects of fasudil, a Rho kinase inhibitor, on hypertension in spontaneously hypertensive rats and on the catecholamine synthetic pathway." | 3.74 | Fasudil attenuates sympathetic nervous activity in the adrenal medulla of spontaneously hypertensive rats. ( Hayashi, M; Kobayashi, S; Kumai, T; Matsumoto, N; Nakaya, S; Takeba, Y; Tsuzuki, Y; Yanagida, Y, 2007) |
| "Fasudil treatment significantly ameliorated those DHF-related myocardial changes." | 1.35 | Long-term inhibition of Rho-kinase ameliorates diastolic heart failure in hypertensive rats. ( Fukui, S; Fukumoto, Y; Kagaya, Y; Nawata, J; Saji, K; Shimokawa, H; Shinozaki, T; Suzuki, J; Tawara, S, 2008) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 17 (60.71) | 29.6817 |
| 2010's | 11 (39.29) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chan, SL | 1 |
| Cipolla, MJ | 1 |
| Ocaranza, MP | 1 |
| Fierro, C | 1 |
| Jalil, JE | 1 |
| Moya, J | 1 |
| Gonzalez, L | 1 |
| Molina, C | 1 |
| Mancilla, C | 1 |
| Vaněčková, I | 2 |
| Behuliak, M | 2 |
| Hojná, S | 1 |
| Kopkan, L | 1 |
| Kadlecová, M | 1 |
| Zicha, J | 2 |
| Yuan, TY | 1 |
| Chen, D | 1 |
| Chen, YC | 1 |
| Zhang, HF | 1 |
| Niu, ZR | 1 |
| Jiao, XZ | 1 |
| Xie, P | 1 |
| Fang, LH | 1 |
| Du, GH | 1 |
| Snelder, N | 1 |
| Ploeger, BA | 1 |
| Luttringer, O | 1 |
| Rigel, DF | 1 |
| Fu, F | 1 |
| Beil, M | 1 |
| Stanski, DR | 1 |
| Danhof, M | 1 |
| Vavřínová, A | 1 |
| Bencze, M | 1 |
| Polgárová, K | 1 |
| Ergang, P | 1 |
| Kuneš, J | 1 |
| Chan, CK | 1 |
| Mak, JC | 1 |
| Man, RY | 1 |
| Vanhoutte, PM | 1 |
| Ying, Z | 1 |
| Yue, P | 1 |
| Xu, X | 1 |
| Zhong, M | 1 |
| Sun, Q | 1 |
| Mikolaj, M | 1 |
| Wang, A | 1 |
| Brook, RD | 1 |
| Chen, LC | 1 |
| Rajagopalan, S | 1 |
| Büssemaker, E | 1 |
| Herbrig, K | 1 |
| Pistrosch, F | 1 |
| Palm, C | 1 |
| Passauer, J | 1 |
| de Frutos, S | 1 |
| Caldwell, E | 1 |
| Nitta, CH | 1 |
| Kanagy, NL | 1 |
| Wang, J | 1 |
| Wang, W | 1 |
| Walker, MK | 1 |
| Gonzalez Bosc, LV | 1 |
| Ray, P | 1 |
| Wright, J | 1 |
| Adam, J | 1 |
| Boucharens, S | 1 |
| Black, D | 1 |
| Brown, AR | 1 |
| Epemolu, O | 1 |
| Fletcher, D | 1 |
| Huggett, M | 1 |
| Jones, P | 1 |
| Laats, S | 1 |
| Lyons, A | 1 |
| de Man, J | 1 |
| Morphy, R | 1 |
| Sherborne, B | 1 |
| Sherry, L | 1 |
| Straten, Nv | 1 |
| Westwood, P | 1 |
| York, M | 1 |
| Guo, P | 1 |
| Wu, C | 1 |
| Masaki, T | 1 |
| Mori, H | 1 |
| Nishiyama, A | 1 |
| Ma, ZP | 1 |
| Jiang, R | 1 |
| Cheng, Y | 1 |
| Yang, HF | 1 |
| Chen, F | 1 |
| Tsounapi, P | 1 |
| Saito, M | 2 |
| Kitatani, K | 1 |
| Dimitriadis, F | 1 |
| Ohmasa, F | 1 |
| Shimizu, S | 1 |
| Kinoshita, Y | 1 |
| Takenaka, A | 1 |
| Satoh, K | 1 |
| Mukai, Y | 1 |
| Kanda, T | 3 |
| Wakino, S | 3 |
| Hayashi, K | 3 |
| Homma, K | 3 |
| Ozawa, Y | 1 |
| Saruta, T | 3 |
| Nakayama, M | 1 |
| Amano, M | 1 |
| Kawabata, S | 1 |
| Kaibuchi, K | 1 |
| Takefuji, M | 1 |
| Jarajapu, YP | 1 |
| Knot, HJ | 1 |
| Yoshioka, K | 1 |
| Tatematsu, S | 1 |
| Hasegawa, K | 1 |
| Takamatsu, I | 1 |
| Sugano, N | 2 |
| Nishikimi, T | 2 |
| Matsuoka, H | 1 |
| Chapados, R | 1 |
| Abe, K | 1 |
| Ihida-Stansbury, K | 1 |
| McKean, D | 1 |
| Gates, AT | 1 |
| Kern, M | 1 |
| Merklinger, S | 1 |
| Elliott, J | 1 |
| Plant, A | 1 |
| Shimokawa, H | 3 |
| Jones, PL | 1 |
| Okamura, N | 1 |
| Mori, A | 1 |
| Sakamoto, K | 1 |
| Kametaka, S | 1 |
| Nakahara, T | 1 |
| Ishii, K | 1 |
| Ishimaru, K | 1 |
| Ueno, H | 1 |
| Kagitani, S | 1 |
| Takabayashi, D | 1 |
| Takata, M | 1 |
| Inoue, H | 1 |
| Kumai, T | 1 |
| Takeba, Y | 1 |
| Matsumoto, N | 1 |
| Nakaya, S | 1 |
| Tsuzuki, Y | 1 |
| Yanagida, Y | 1 |
| Hayashi, M | 1 |
| Kobayashi, S | 1 |
| Fukui, S | 1 |
| Fukumoto, Y | 1 |
| Suzuki, J | 1 |
| Saji, K | 1 |
| Nawata, J | 1 |
| Tawara, S | 1 |
| Shinozaki, T | 1 |
| Kagaya, Y | 1 |
| Masumoto, A | 1 |
| Hirooka, Y | 1 |
| Hironaga, K | 1 |
| Setoguchi, S | 1 |
| Takeshita, A | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Efficacy of Early Intracoronary Administration of Fasudil Hydrochloride on Myocardial Perfusion in the Primary PCI of ST-elevation Myocardial Infarction: an Prospective, Randomized and Multicenter Trial[NCT03753269] | Phase 4 | 600 participants (Anticipated) | Interventional | 2019-07-01 | Not yet recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
4 reviews available for fasudil and Hypertension
| Article | Year |
|---|---|
[Involvement of small GTPase Rho and Rho-kinase in the pathogenesis of hypertension and hypertensive target organ damage].
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Amides; Angina Pectoris; Animals; Arteriosclerosis; C | 2004 |
Molecular mechanisms and therapeutic strategies of chronic renal injury: renoprotective effect of rho-kinase inhibitor in hypertensive glomerulosclerosis.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Blood Pressure; Collagen; Disease Models, An | 2006 |
Molecular mechanisms and therapeutic strategies of chronic renal injury: role of rho-kinase in the development of renal injury.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Angiotensin II; Animals; Cyclin-Dependent Kinase Inhi | 2006 |
[Role of the Rho/Rho-kinase pathway in the development of hypertensive glomerulosclerosis: renoprotective effect of Rho-kinase inhibitor in hypertensive glomerulosclerosis and its molecular mechanism].
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Disease Models, Animal; Glomerulosclerosis, | 2006 |
1 trial available for fasudil and Hypertension
| Article | Year |
|---|---|
Possible involvement of Rho-kinase in the pathogenesis of hypertension in humans.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Enzyme Inhibitors; Female; Forearm; Humans; Hypertens | 2001 |
23 other studies available for fasudil and Hypertension
| Article | Year |
|---|---|
Treatment with low dose fasudil for acute ischemic stroke in chronic hypertension.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Cerebrovascular Circulation; Chronic Disease | 2017 |
Rho kinase activation in circulating leukocytes is related to hypertensive myocardial remodeling.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Atrial Remodeling; Blood Pressure; Cardiomeg | 2018 |
Exaggerated blood pressure response to fasudil or nifedipine in hypertensive Ren-2 transgenic rats: role of altered baroreflex.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Baroreflex; Blood Pressure; Calcium Channel | 2019 |
A novel hypertensive crisis rat model established by excessive norepinephrine infusion and the potential therapeutic effects of Rho-kinase inhibitors on it.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Antihypertensive Agents; Blood Pressure; Hyp | 2019 |
Drug effects on the CVS in conscious rats: separating cardiac output into heart rate and stroke volume using PKPD modelling.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Amiloride; Amlodipine; Animals; Atropine; Enalapril; | 2014 |
Ontogenetic changes in contribution of calcium sensitization and calcium entry to blood pressure maintenance of Wistar-Kyoto and spontaneously hypertensive rats.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Arteries; Blood Pressure; Calcium; Calcium C | 2015 |
Rho kinase inhibitors prevent endothelium-dependent contractions in the rat aorta.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Amides; Animals; Antihypertensive Agents; Aorta, Thor | 2009 |
Air pollution and cardiac remodeling: a role for RhoA/Rho-kinase.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Angiotensin II; Animals; Atmosphere Exposure Chambers | 2009 |
Role of rho-kinase in the regulation of vascular tone in hypertensive renal transplant recipients.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Case-Control Studies; Dose-Response Relationship, Dru | 2009 |
NFATc3 contributes to intermittent hypoxia-induced arterial remodeling in mice.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Actins; Animals; Aorta, Thoracic; Bosentan; Dioxoles; | 2010 |
Optimisation of 6-substituted isoquinolin-1-amine based ROCK-I inhibitors.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Amines; Animals; Disease Models, Animal; Hypertension | 2011 |
Subdose of fasudil suppresses myocardial fibrosis in aldosterone-salt-treated uninephrectomized rats.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Aldosterone; Animals; Antihypertensive Agents; Biomar | 2011 |
[Fasudil improves erectile function of hypertensive rats].
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Hypertension; Male; Penile Erection; Rats; R | 2012 |
Fasudil improves the endothelial dysfunction in the aorta of spontaneously hypertensive rats.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Aorta; Endothelium, Vascular; Gene Expressio | 2012 |
[Involvement of Rho-kinase in hypertensive vascular disease--a novel therapeutic target in hypertension].
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Blood Vessels; Cardiovascular Diseases; Hype | 2002 |
Effect of fasudil on Rho-kinase and nephropathy in subtotally nephrectomized spontaneously hypertensive rats.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Blood Pressure; Cell Cycle Proteins; Cell Di | 2003 |
Relative contribution of Rho kinase and protein kinase C to myogenic tone in rat cerebral arteries in hypertension.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Alkaloids; Amides; Animals; Benzophenanthridines; Blo | 2005 |
Rho-kinase as a molecular target for insulin resistance and hypertension.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Acetylcholine; Animals; Arterioles; Cell Line; Glucos | 2006 |
ROCK controls matrix synthesis in vascular smooth muscle cells: coupling vasoconstriction to vascular remodeling.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Actins; Animals; Blood Vessels; Cell Adhesion; Cell S | 2006 |
Vasodilator effects of fasudil, a Rho-kinase inhibitor, on retinal arterioles in stroke-prone spontaneously hypertensive rats.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Analysis of Variance; Animals; Blood Pressure; Dose-R | 2007 |
Fasudil attenuates myocardial fibrosis in association with inhibition of monocyte/macrophage infiltration in the heart of DOCA/salt hypertensive rats.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Blood Pressure; Cytokines; Desoxycorticoster | 2007 |
Fasudil attenuates sympathetic nervous activity in the adrenal medulla of spontaneously hypertensive rats.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Adrenal Medulla; Animals; Blood Pressure; Blotting, W | 2007 |
Long-term inhibition of Rho-kinase ameliorates diastolic heart failure in hypertensive rats.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Blotting, Western; Disease Models, Animal; D | 2008 |